After re-examining its initial opinion, the European Medicines Agency has confirmed its recommendation to refuse marketing authorisation for the medicine Nouryant. The medicine was intended for the treatment of Parkinson’s disease.
The Agency issued its opinion after re-examination on 11 November 2021. The Agency had issued its initial opinion on 22 July 2021. The company that applied for authorisation of Nouryant is Kyowa Kirin Holdings B.V.
Questions and answers on the refusal of the marketing authorisation for Nouryant (istradefylline) (PDF/111.36 KB)
First published: 23/07/2021
Last updated: 19/01/2022
|International non-proprietary name (INN) or common name||
|Therapeutic area (MeSH)||
|Anatomical therapeutic chemical (ATC) code||
Kyowa Kirin Holdings B.V.
|Date of opinion||
|Date of refusal of marketing authorisation||